The gamma delta T/NK cell product GADEKILL as a novel immunotherapeutic tool for neuroblastoma patients: role of B7H6 and BTN2A1 in tumor cell killing | Synapse
March 3, 2026Open Access
The gamma delta T/NK cell product GADEKILL as a novel immunotherapeutic tool for neuroblastoma patients: role of B7H6 and BTN2A1 in tumor cell killing
Puntos clave
GADEKILL exhibits notable antineuroblastoma activity, especially in relapsed or refractory cases.
This product targets tumor cells using defined mechanisms involving b7h6 and btn2a1 pathways.
The analysis highlights low GD2 expression's significance in treatment efficacy against neuroblastoma.
These findings may enable further development of GADEKILL as an effective immunotherapeutic option.
Resumen
Our study demonstrated the potential antineuroblastoma activity of the GADEKILL, supporting its therapeutic use, particularly in the context of relapsed/refractory R/R HR-NB with low GD2 expression.